Ftse Mib
31.876,64
0,42%
DAX
17.729,09
0,35%
S&P 500
5.319,31
2,30%
NASDAQ
16.660,02
2,87%
Bitcoin
60.702,90
-1,67%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Imunon Inc (IMNN) Imunon Inc (IMNN) Notizie

IMNN

Imunon (IMNN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMNN
DataOraFonteTitoloSimboloCompagnia
07/08/202423:04GlobeNewswire Inc.IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024NASDAQ:IMNNImunon Inc
05/08/202417:53Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IMNNImunon Inc
01/08/202414:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
01/08/202412:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNNImunon Inc
31/07/202414:00GlobeNewswire Inc.IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:IMNNImunon Inc
30/07/202414:00GlobeNewswire Inc.IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001NASDAQ:IMNNImunon Inc
29/07/202422:05GlobeNewswire Inc.IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer TomorrowNASDAQ:IMNNImunon Inc
24/06/202414:30GlobeNewswire Inc.IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
14/06/202412:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
10/06/202420:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
05/06/202414:30GlobeNewswire Inc.First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialNASDAQ:IMNNImunon Inc
23/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNNImunon Inc
15/05/202422:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMNNImunon Inc
15/05/202414:30GlobeNewswire Inc.Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingNASDAQ:IMNNImunon Inc
13/05/202415:00GlobeNewswire Inc.IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyNASDAQ:IMNNImunon Inc
13/05/202414:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNNImunon Inc
13/05/202414:00GlobeNewswire Inc.IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
08/05/202414:00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202417:00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202414:30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202414:00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202413:00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202413:30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202422:00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202413:00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202422:00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202414:30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202414:30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202414:00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202422:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMNN

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
G
Generali
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
LDO
Leonardo
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
FBK
Finecobank
BIT
BAMI
Banco BPM
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network